Organisation paid for research Program year 2025 Source: CMS Open Payments

Prestige Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$886,180

1,089 payments

Through program year 2025, Prestige Clinical Research is reported as receiving $886,180 in research payments, across 1,089 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$72,788	3
2024	Research	$22,863	1
2023	Research	$10,681	3
2022	Research	$33,950	48
2021	Research	$182,996	716
2020	Research	$211,928	164
2019	Research	$350,975	154

Breakdown

Who paid Research payments · program years 2019–2025

Pfizer Inc. $313,557 37 payments
Novo Nordisk AS $307,007 963 payments
Kowa Research Institute, Inc. $106,075 31 payments
Merck Sharp & Dohme Corporation $95,651 4 payments
Esperion Therapeutics, Inc. $23,680 39 payments
Janssen Research & Development, LLC $20,692 7 payments
Ironwood Pharmaceuticals, Inc $11,519 4 payments
Shire North American Group Inc $8,000 4 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine 20Vpnc When Coadministered With Seasonal Inactivated Influenza Vaccine Siiv in Adults 65 Years of Age $176,485 13 payments
Nn9838-4433 $114,056 140 payments
A Phase 3 Randomized Openlabel Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Adults 65 Years of Age With Prior Pneumococcal Vaccination $114,020 16 payments
Nn1436-4477 $72,837 408 payments
K-877-302 $68,698 18 payments
Nn9924-4635 $50,715 82 payments
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression $47,544 1 payment
K-877-302 $30,782 9 payments
Nn2211-4232 $28,616 4 payments
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $23,680 39 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.